Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001883850-23-000088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-12 | 2023-12-11 | REGN | McCourt Marion | EVP Commercial | S - Sale | $838.44 | -270 | 20.8K | -1% | -$226.4K |
| D | 2023-12-12 | 2023-12-08 | REGN | McCourt Marion | EVP Commercial | A - Grant | $0.00 | +2,133 | 21.1K | +11% | $0 |
| DM | 2023-12-12 | 2023-12-08+ | REGN | McCourt Marion | EVP Commercial | F - Tax | $843.88 | -1,225 | 20.4K | -6% | -$1.03M |
| D | 2023-12-12 | 2023-12-08 | REGN | McCourt Marion | EVP Commercial | A - Grant | $0.00 | +7,649 | 7,649 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-11 | S | D | 270 | $838.44 | 20,814 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-08 | A | A | 2,133 | $0.00 | 21,084 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-08 | F | D | 852 | $843.79 | 18,951 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-11 | F | D | 373 | $844.09 | 20,441 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-08 | A | A | 7,649 | $0.00 | 7,649 | D | $843.79 · — to 2033-12-08 | 7,649 Common Stock | (F3) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |